 | • レポートコード：C-PMR-JN043 • 出版社/出版日：Persistence Market Research / 2018年10月 • レポート形態：英文、PDF、181ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：ライフサイエンス・トランスフォーメーションヘルス |
| Individual（１名、印刷不可） | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User（５名） | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Corporate User | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
Persistence Market Research offers an eight year forecast on the global Cushing’s syndrome and Acromegaly Treatment market. The primary objective of the report is to offer updates and information related to the opportunities in the Cushing’s syndrome and Acromegaly Treatment market.
Report Description
In terms of revenue, the global Cushing’s syndrome and Acromegaly treatment market is expected to register a CAGR of 9.3% during the forecast period, 2018–2026. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global Cushing’s syndrome and Acromegaly treatment market over the forecast period. Insights on the key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global Cushing’s syndrome and Acromegaly treatment market are presented in the report.
The global market for Cushing’s syndrome and Acromegaly treatment is expected to witness higher single digit growth value owing to the growing prevalence and rates of screening of Cushing’s syndrome and acromegaly, growth in awareness and development of healthcare infrastructure. The increase in incidence of Cushing’s syndrome and Acromegaly is the major factor driving the growth of the global Cushing’s syndrome and Acromegaly treatment market. The advances in imaging such as advent of magnetic resonance imaging, computed tomography and among others are increasing the adoption of Cushing’s syndrome and Acromegaly treatment. The demand for non-invasive treatment coupled with the relapse rates of Cushing’s syndrome and Acromegaly after surgery is driving a large adoption of drug treatment for Cushing’s syndrome and Acromegaly Treatment market.
Increasing investments in the research and development coupled with the entry of deep pocketed companies in the Cushing’s syndrome and Acromegaly treatment market is expected to generate momentum and growth opportunities for the Cushing’s syndrome and Acromegaly Treatment market. The manufacturers are focusing on the production of targeted therapies and technologically advanced products. Technological advancements is resulting in faster product development and shorter lifecycles of the products.
The report does not includes the revenue generated by the sale of Cushing’s syndrome and Acromegaly products used in fields other than treatment. Currency fluctuations and inflation are not considered while calculating the revenue of the Cushing’s syndrome and Acromegaly treatment market.
Revenue from the Cushing’s syndrome and Acromegaly treatment market in countries of Asia Pacific such as China is expected to expand at the relatively higher CAGR due to lower install base, which reflects high market equity and developing healthcare infrastructure. To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the product type, indications, end users and regions. The report provides analysis of the global Cushing’s syndrome and Acromegaly treatment market in terms of market value (US$ Mn).
By drug type, the global Cushing’s syndrome and Acromegaly treatment market is segmented into Cushing’s syndrome treatment and Acromegaly treatment. The Cushing’s syndrome treatment is further sub segmented into Glucocorticoid Receptor Inhibitors, Somatostatin, Ketoconazole HRA, and other Off-label. The Acromegaly treatment is further sub segmented into Somatostatin, Glucocorticoid Receptor Inhibitors, and other Off-label. Based on the distribution channels, the global Cushing’s syndrome and Acromegaly treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The report begins with the market definition of Cushing’s syndrome and Acromegaly treatment, followed by definitions of the different segment types. The market dynamics section includes an analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global Cushing’s syndrome and Acromegaly treatment market.
The report analyses the Cushing’s syndrome and Acromegaly treatment market on the basis of the drug types and distribution channels and presents forecast in terms of value for the next 10 years. On the basis of drug types, the global Cushing’s syndrome and Acromegaly treatment market is segmented into:
Cushing’s Syndrome Treatment
Glucocorticoid Receptor Inhibitors
Somatostatin
Ketoconazole HRA
Other Off-label
Acromegaly Treatment
Somatostatin
Glucocorticoid Receptor Inhibitors
Other Off-label
On the basis of the distribution channels, the global Cushing’s syndrome and Acromegaly treatment market is segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 10 years. On the basis of region, the global Cushing’s syndrome and Acromegaly treatment market is segmented into:
North America
U.S.
Canada
Western Europe
Germany
France
U.K.
Russia
Spain
Rest of Western Europe
Latin America
Brazil
Mexico
Rest of Latin America
Asia Pacific
Australia
China
Japan
India
Rest of Asia Pacific
Rest of World
GCC Countries
South Africa
Rest of World
In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global Cushing’s syndrome and Acromegaly treatment market.
Another key feature of this report is the analysis of the key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by the Cushing’s syndrome and Acromegaly treatment market. To understand the key segments in terms of their growth and performance in the global Cushing’s syndrome and Acromegaly treatment market, Persistence Market Research has developed a market attractiveness index. The resulting index will help identify the existing market opportunities in Cushing’s syndrome and Acromegaly treatment market.
In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of the key companies operating in the global Cushing’s syndrome and Acromegaly treatment market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the Cushing’s syndrome and Acromegaly treatment market. However, this section also includes market strategies and SWOT analysis of the key players operating in the global Cushing’s syndrome and Acromegaly treatment market.
Detailed profiles of the manufacturers of Cushing’s syndrome and Acromegaly Treatment are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the Cushing’s syndrome and Acromegaly treatment market are Novartis AG, Corcept Therapeutics, HRA Pharma, Bristol-Myers Squibb Company, Pfizer Inc., Ipsen Biopharmaceuticals, Inc. among others.
レポート目次1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Cushing’s Disease and Acromegaly Treatment Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Market Evolution
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Demand Side
4.2.1.2. Supply Side
4.2.2. Restraints
4.2.3. Market Trends
5. Key Inclusions
5.1. Key Regulations
5.2. Pipeline Analysis
5.3. Epidemiology of Cushing’s Disease and Acromegaly, By Region
5.4. Global Pituitary Disorders Treatment Market Overview (2017)
6. North America Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017 and Forecast 2018–2026
6.1. Introduction
6.2. Historical Market Size (US$ Mn) & Analysis By Country, 2013-2017
6.2.1. U.S.
6.2.2. Canada
6.3. Market Size (US$ Mn) & Forecast By Country, 2018–2026
6.4. Historical Market Size (US$ Mn) By Drug Type, 2013-2017
6.4.1. Cushing’s Syndrome Treatment
6.4.1.1. Glucocorticoid Receptor Inhibitors
6.4.1.1.1. Aminoglutethimide (Cytadren)
6.4.1.1.2. Mifepristone
6.4.1.2. Somatostatin (e.g. pasireotide)
6.4.1.3. Ketoconazole HRA
6.4.1.4. Other Off-label drugs
6.4.2. Acromegaly Treatment
6.4.2.1. Somatostatin
6.4.2.1.1. Octreotide
6.4.2.1.2. Lanreotide
6.4.2.1.3. Pasireotide
6.4.2.2. Glucocorticoid Receptor Inhibitors (e.g. Pegvisomant)
6.4.2.3. Other Off-label Drugs (e.g. cabergolin etc.)
6.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
6.6. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
6.6.1. Hospital Pharmacies
6.6.2. Retail Pharmacies
6.6.3. Drug Stores
6.6.4. Clinics
6.6.5. Online Pharmacies
6.7. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018–2026
6.8. Market Attractiveness Analysis
6.8.1. By Country
6.8.2. By Drug Type
6.8.3. By Distribution Channel
6.9. Drivers and Restraints: Impact Analysis
7. Latin America Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017and Forecast 2018–2026
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Trends and Analysis By Country, 2013-2017
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Market Size (US$ Mn) & Forecast By Country, 2018–2026
7.4. Historical Market Size (US$ Mn) By Drug Type, 2013-2017
7.4.1. Cushing’s Syndrome Treatment
7.4.1.1. Glucocorticoid Receptor Inhibitors
7.4.1.1.1. Aminoglutethimide (Cytadren)
7.4.1.1.2. Mifepristone
7.4.1.2. Somatostatin (e.g. pasireotide)
7.4.1.3. Ketoconazole HRA
7.4.1.4. Other Off-label drugs
7.4.2. Acromegaly Treatment
7.4.2.1. Somatostatin
7.4.2.1.1. Octreotide
7.4.2.1.2. Lanreotide
7.4.2.1.3. Pasireotide
7.4.2.2. Glucocorticoid Receptor Inhibitors (e.g. Pegvisomant)
7.4.2.3. Other Off-label Drugs (e.g. cabergolin etc.)
7.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
7.6. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
7.6.1. Hospital Pharmacies
7.6.2. Retail Pharmacies
7.6.3. Drug Stores
7.6.4. Clinics
7.6.5. Online Pharmacies
7.7. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018–2026
7.8. Market Attractiveness Analysis
7.8.1. By Country
7.8.2. By Drug Type
7.8.3. By Distribution Channel
7.9. Drivers and Restraints: Impact Analysis
8. Europe Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017and Forecast 2018–2026
8.1. Introduction
8.2. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2013-2017
8.2.1. Germany
8.2.2. U.K.
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Market Size (US$ Mn) & Forecast By Country, 2018–2026
8.4. Historical Market Size (US$ Mn) By Drug Type, 2013-2017
8.4.1. Cushing’s Syndrome Treatment
8.4.1.1. Glucocorticoid Receptor Inhibitors
8.4.1.1.1. Aminoglutethimide (Cytadren)
8.4.1.1.2. Mifepristone
8.4.1.2. Somatostatin (e.g. pasireotide)
8.4.1.3. Ketoconazole HRA
8.4.1.4. Other Off-label drugs
8.4.2. Acromegaly Treatment
8.4.2.1. Somatostatin
8.4.2.1.1. Octreotide
8.4.2.1.2. Lanreotide
8.4.2.1.3. Pasireotide
8.4.2.2. Glucocorticoid Receptor Inhibitors (e.g. Pegvisomant)
8.4.2.3. Other Off-label Drugs (e.g. cabergolin etc.)
8.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
8.6. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
8.6.1. Hospital Pharmacies
8.6.2. Retail Pharmacies
8.6.3. Drug Stores
8.6.4. Clinics
8.6.5. Online Pharmacies
8.7. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018–2026
8.8. Market Attractiveness Analysis
8.8.1. By Country
8.8.2. By Drug Type
8.8.3. By Distribution Channel
8.9. Drivers and Restraints: Impact Analysis
9. Asia Pacific Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017 and Forecast 2018–2026
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. Australia and New Zealand
9.2.5. Rest of Asia Pacific
9.3. Market Size (US$ Mn) & Forecast By Country, 2018–2026
9.4. Historical Market Size (US$ Mn) By Drug Type, 2013-2017
9.4.1. Cushing’s Syndrome Treatment
9.4.1.1. Glucocorticoid Receptor Inhibitors
9.4.1.1.1. Aminoglutethimide (Cytadren)
9.4.1.1.2. Mifepristone
9.4.1.2. Somatostatin (e.g. pasireotide)
9.4.1.3. Ketoconazole HRA
9.4.1.4. Other Off-label drugs
9.4.2. Acromegaly Treatment
9.4.2.1. Somatostatin
9.4.2.1.1. Octreotide
9.4.2.1.2. Lanreotide
9.4.2.1.3. Pasireotide
9.4.2.2. Glucocorticoid Receptor Inhibitors (e.g. Pegvisomant)
9.4.2.3. Other Off-label Drugs (e.g. cabergolin etc.)
9.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
9.6. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
9.6.1. Hospital Pharmacies
9.6.2. Retail Pharmacies
9.6.3. Drug Stores
9.6.4. Clinics
9.6.5. Online Pharmacies
9.7. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018–2026
9.8. Market Attractiveness Analysis
9.8.1. By Country
9.8.2. By Drug Type
9.8.3. By Distribution Channel
9.9. Drivers and Restraints: Impact Analysis
10. Middle East & Africa Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017and Forecast 2018–2026
10.1. Introduction
10.2. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2013-2017
10.2.1. GCC Countries
10.2.2. South Africa
10.2.3. Rest of MEA
10.3. Market Size (US$ Mn) & Forecast By Country, 2018–2026
10.4. Historical Market Size (US$ Mn) By Drug Type, 2013-2017
10.4.1. Cushing’s Syndrome Treatment
10.4.1.1. Glucocorticoid Receptor Inhibitors
10.4.1.1.1. Aminoglutethimide (Cytadren)
10.4.1.1.2. Mifepristone
10.4.1.2. Somatostatin (e.g. pasireotide)
10.4.1.3. Ketoconazole HRA
10.4.1.4. Other Off-label drugs
10.4.2. Acromegaly Treatment
10.4.2.1. Somatostatin
10.4.2.1.1. Octreotide
10.4.2.1.2. Lanreotide
10.4.2.1.3. Pasireotide
10.4.2.2. Glucocorticoid Receptor Inhibitors (e.g. Pegvisomant)
10.4.2.3. Other Off-label Drugs (e.g. cabergolin etc.)
10.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
10.6. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Drug Stores
10.6.4. Clinics
10.6.5. Online Pharmacies
10.7. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018–2026
10.8. Market Attractiveness Analysis
10.8.1. By Country
10.8.2. By Drug Type
10.8.3. By Distribution Channel
10.9. Drivers and Restraints: Impact Analysis
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Analysis
13.1. Competition Dashboard
13.2. Market Tier Structure Analysis
13.3. Brand Share Analysis (2017)
13.3.1. Cushing’s Disease Brand Share Analysis
13.3.2. Acromegaly Brand Share Analysis
13.4. Company Deep Dive
13.4.1. Novartis AG
13.4.1.1. Overview
13.4.1.2. Product and Application Portfolio
13.4.1.3. Production Footprint
13.4.1.4. Sales Footprint
13.4.1.5. Channel Footprint
13.4.1.6. Strategy
13.4.1.6.1.1. Marketing Strategy
13.4.1.6.1.2. Product Strategy
13.4.1.6.1.3. Channel Strategy
13.4.2. Corcept Therapeutics
13.4.2.1. Overview
13.4.2.2. Product and Application Portfolio
13.4.2.3. Production Footprint
13.4.2.4. Sales Footprint
13.4.2.5. Channel Footprint
13.4.2.6. Strategy
13.4.2.6.1.1. Marketing Strategy
13.4.2.6.1.2. Product Strategy
13.4.2.6.1.3. Channel Strategy
13.4.3. HRA Pharma
13.4.3.1. Overview
13.4.3.2. Product and Application Portfolio
13.4.3.3. Production Footprint
13.4.3.4. Sales Footprint
13.4.3.5. Channel Footprint
13.4.3.6. Strategy
13.4.3.6.1.1. Marketing Strategy
13.4.3.6.1.2. Product Strategy
13.4.3.6.1.3. Channel Strategy
13.4.4. Bristol-Myers Squibb Company
13.4.4.1. Overview
13.4.4.2. Product and Application Portfolio
13.4.4.3. Production Footprint
13.4.4.4. Sales Footprint
13.4.4.5. Channel Footprint
13.4.4.6. Strategy
13.4.4.6.1.1. Marketing Strategy
13.4.4.6.1.2. Product Strategy
13.4.4.6.1.3. Channel Strategy
13.4.5. Pfizer Inc.
13.4.5.1. Overview
13.4.5.2. Product and Application Portfolio
13.4.5.3. Production Footprint
13.4.5.4. Sales Footprint
13.4.5.5. Channel Footprint
13.4.5.6. Strategy
13.4.5.6.1.1. Marketing Strategy
13.4.5.6.1.2. Product Strategy
13.4.5.6.1.3. Channel Strategy
13.4.6. Ipsen Biopharmaceuticals, Inc.
13.4.6.1. Overview
13.4.6.2. Product and Application Portfolio
13.4.6.3. Production Footprint
13.4.6.4. Sales Footprint
13.4.6.5. Channel Footprint
13.4.6.6. Strategy
13.4.6.6.1.1. Marketing Strategy
13.4.6.6.1.2. Product Strategy
13.4.6.6.1.3. Channel Strategy
14. Global Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017and Forecast 2018–2026, By Region
14.1. Introduction/Key Findings
14.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013-2017
14.3. Market Size (US$ Mn) Forecast By Region, 2018–2026
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. Asia Pacific
14.3.5. Middle East & Africa
14.4. Market Attractiveness Analysis By Region
15. Global Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017and Forecast 2018–2026, By Drug Type
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) By Drug Type, 2013-2017
15.2.1. Cushing’s Syndrome Treatment
15.2.1.1. Glucocorticoid Receptor Inhibitors
15.2.1.1.1. Aminoglutethimide (Cytadren)
15.2.1.1.2. Mifepristone
15.2.1.2. Somatostatin (e.g. pasireotide)
15.2.1.3. Ketoconazole HRA
15.2.1.4. Other Off-label drugs
15.2.2. Acromegaly Treatment
15.2.2.1. Somatostatin
15.2.2.1.1. Octreotide
15.2.2.1.2. Lanreotide
15.2.2.1.3. Pasireotide
15.2.2.2. Glucocorticoid Receptor Inhibitors (e.g. Pegvisomant)
15.2.2.3. Other Off-label Drugs (e.g. cabergolin etc.)
15.3. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
15.4. Market Attractiveness Analysis By Drug Type
16. Global Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017and Forecast 2018–2026, By Distribution Channel
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
16.2.1. Hospital Pharmacies
16.2.2. Retail Pharmacies
16.2.3. Drug Stores
16.2.4. Clinics
16.2.5. Online Pharmacies
16.3. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018–2026
16.4. Market Attractiveness Analysis By Distribution Channel
17. Global Cushing’s Disease and Acromegaly Treatment Market Analysis 2013-2017and Forecast 2018–2026
17.1. Market Value Share Analysis
17.2. Y-o-Y Growth Analysis
17.3. Absolute $ Opportunity
18. Research Methodology
List of tablesTable 01: North America Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Country
Table 02: North America Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Drug Type
Table 03: North America Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Distribution Channel
Table 04: Europe Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Country
Table 05: Europe Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Drug Type
Table 06: Europe Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Distribution Channel
Table 07: Latin America Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Country
Table 08: Latin America Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Drug Type
Table 09: Latin America Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Distribution Channel
Table 10: APAC Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Country
Table 11: APAC Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Drug Type
Table 12: APAC Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Distribution Channel
Table 13: MEA Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Country
Table 14: MEA Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Drug Type
Table 15: MEA Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Distribution Channel
Table 16: Global Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Region
Table 17: Global Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Drug Type
Table 18: Global Cushing’s Syndrome and Acromegaly Treatment Market Value (US$ Mn) Analysis and Forecast 2016 – 2026, by Distribution Channel